Regenxbio will construct a GMP facility in Maryland to produce adeno-associated viral vectors for its gene therapy programs using its NAV technology-based platform.
The good manufacturing practice (GMP) plant will be integrated into Regenxbio’s 132,000 square-foot headquarters in Rockville, Maryland, currently under construction. Financial details have not been disclosed but the manufacturing plant is expected to be operational in 2021.
{iframe}https://bioprocessintl.com/bioprocess-insider/facilities-capacity/regenxbio-building-maryland-aav-plant-to-support-gene-therapies/{/iframe}